XML 21 R11.htm IDEA: XBRL DOCUMENT v3.8.0.1
Balance Sheet Components
 9 Months Ended
Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Balance Sheet Components
Balance Sheet Components

Cash Equivalents and Available-for-sale Securities

Cash equivalents and available-for-sale securities consisted of the following (in thousands):
 
September 30, 2017
 
Amortized
Cost
 
Gross Unrealized
 
 
 
Gains
 
Losses
 
Fair Value
Money market funds
$
47,638

 
$
—

 
$
—

 
$
47,638

Corporate bonds
7,502

 
—

 
(7
)
 
7,495

Government bonds
47,056

 
—

 
(44
)
 
47,012

Total cash equivalents and available-for-sale securities
$
102,196

 
$
—

 
$
(51
)
 
$
102,145

Classified as:
 
 
 
 
 
 
 
Cash equivalents
 
 
 
 
 
 
$
47,638

Available-for-sale securities - current
 
 
 
 
 
 
43,191

Available-for-sale securities - noncurrent
 
 
 
 
 
 
11,316

Total cash equivalents and available-for-sale securities
 
 
 
 
 
 
$
102,145


 
December 31, 2016
 
Amortized
Cost
 
Gross Unrealized
 
 
 
Gains
 
Losses
 
Fair Value
Money market funds
$
11,270

 
$
—

 
$
—

 
$
11,270

Corporate bonds
21,886

 
—

 
(45
)
 
21,841

Commercial paper
10,769

 
—

 
—

 
10,769

Government bonds
41,316

 
2

 
(29
)
 
41,289

Total cash equivalents and available-for-sale securities
$
85,241

 
$
2

 
$
(74
)
 
$
85,169

Classified as:
 
 
 
 
 
 
 
Cash equivalents
 
 
 
 
 
 
$
18,504

Available-for-sale securities - current
 
 
 
 
 
 
56,515

Available-for-sale securities - noncurrent
 
 
 
 
 
 
10,150

Total cash equivalents and available-for-sale securities
 
 
 
 
 
 
$
85,169



All available-for-sale securities - current held as of September 30, 2017 and December 31, 2016 had contractual maturities of less than one year. All available-for-sale securities - noncurrent held as of September 30, 2017 and December 31, 2016 had contractual maturities of at least one year but less than two years. There have been no material realized gains or losses on available-for-sale securities for the periods presented.

Accrued Expenses and Other Payables

Accrued expenses and other payables consisted of the following (in thousands):
 
September 30, 2017
 
December 31, 2016
Accrued clinical and research related expenses
$
5,864

 
$
3,617

Accrued employee related expenses
1,611

 
1,420

Accrued professional service fees
709

 
115

Other
57

 
120

Total accrued expenses and other payables
$
8,241

 
$
5,272